Navigation Links
PharMEDium Registers with FDA as an 'Outsourcing Facility' Under New Drug Quality and Security Act
Date:12/9/2013

LAKE FOREST, Ill., Dec. 9, 2013 /PRNewswire/ -- PharMEDium announced today that it is registered with the U.S. Food and Drug Administration (FDA) as a 503B large-scale sterile compounding "outsourcing facility" under the recently enacted Drug Quality and Security Act (DQSA).

The law, signed by the President on November 27, 2013, calls for large-scale entities engaged in non-prescription anticipatory compounding to voluntarily register with the FDA under the newly created section 503B of the federal Food, Drug, and Cosmetic (FDC) Act.

"Our customers can continue to expect a high level of disclosure and transparency based on this new official outsourcing facility category and clarifying rules that govern it," said David Jonas, Chairman and CEO of PharMEDium Healthcare Corp. "Going forward, there will be more consistent regulations and consistent oversight, which should raise the level of confidence among hospital leaders, providers and their patients."

FDA urges providers to purchase from registered compounders

During a media briefing last week, FDA Commissioner Margaret Hamburg, MD, said: "Helping to protect Americans from unsafe drugs is among the FDA's highest priorities and is part of our core mission." She explained that the DQSA "represents a step forward by creating a new pathway in which a compounder can register with FDA as an outsourcing facility."

Dr. Hamburg said that the section of the new law pertaining to compounders will give healthcare providers and health networks greater safeguards as related to medication safety if they purchase compounded products from registered outsourcing facilities.

"If compounders register with FDA as outsourcers, hospitals and other healthcare providers will be able to provide their patients with drugs that were compounded in facilities that are subject to increased FDA oversight, including inspections on a risk-based schedule, and federal requirements for current good manufacturing process, among others," Dr. Hamburg said.

She added: "With that in mind, we'll be encouraging healthcare providers and health networks to consider strongly purchasing compounded products from FDA-registered and regulated facilities. This will be a critical step they can take to better ensure the health and safety of their patients."

Dr. Hamburg said that FDA will be posting a list of registered compounders on its website to serve as a resource for healthcare providers, facilities and networks.

A transcript of the full media briefing is available at: www.fda.gov/NewsEvents/Newsroom/MediaTranscripts/ucm334695.htm.

Clearer authority, stronger oversight for FDA

"PharMEDium has long advocated for clearer FDA authority and stronger oversight and believes that when the law is implemented swiftly and fully, the DQSA will help prevent another national tragedy like last year's devastating fungal meningitis outbreak," said Rich Kruzynski, President of PharMEDium. The company has been voluntarily registered with the FDA since the company's inception — more than a decade before it was requested by this much-needed new law.

The 503B registration obligates outsourcing facilities to comply with FDA oversight, manufacturing-like safety standards and routine inspection by the Agency. If an entity declines to register with the FDA, then it is not an "outsourcing facility," and its operation will be regulated under a different section of the FDC Act, 503A. Entities that do not elect to become 503B registrants and are engaged in large-scale anticipatory compounding without prescriptions are likely in violation of one or more provisions of the FDC Act if they are not inspected to the higher level of the FDA.

PharMEDium's registration as an outsourcing facility under the DQSA is based on draft guidance released by the FDA and listed in the Federal Register on December 4, 2013. Apart from the registration instructions, the draft guidance includes new drug labeling and drug event reporting regulations, and it also requires outsourcing facilities to submit a detailed report to the FDA identifying all drugs compounded by the facility during the previous six-month period. PharMEDium is actively engaged in complying with all draft guidelines.

Who we are: 

PharMEDium is the nation's leading provider of hospital pharmacy-outsourced, sterile admixture services with centers in four states and thousands of acute care hospital customers nationwide. Our qualified personnel and state-of-the-art centers are registered with the FDA, licensed by states as compounding pharmacies, and governed by our own rigorous quality standards. We begin the compounding process with FDA-approved sterile drugs, diluent and containers from FDA-approved manufacturers. It is our mission to be the preeminent provider of choice for hospital customers and to attain the highest degree of integrity in the compounding of sterile preparations.


'/>"/>
SOURCE PharMEDium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
2. PharMEDium Encourages Swift Action to Strengthen Federal Oversight of Advanced Sterile Compounding
3. PharMEDium Supports Draft Legislation, Efforts to Strengthen Oversight of the Compounding Industry
4. PharMEDium Applauds Passage of Legislation to Strengthen Oversight of the Compounding Industry
5. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
6. Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference
7. Millstone Medical Outsourcing Hires New Vice President Quality
8. Emerging Trends in Medical Device Outsourcing and Contract Manufacturing
9. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
10. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
11. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology:
(Date:6/23/2017)... , ... June 23, 2017 , ... Everybody has their ... while others prefer to read it, and some people don't like it at all. ... Here's what they found: , Erotic literature can give readers a taste of their ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia Leaders Selected ... from government, business and civil society in 11 countries across the Middle East and ... in a transformative exchange of knowledge and ideas with the leading minds in their ...
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
Breaking Medicine News(10 mins):